Reported Q: Q3 2025 Rev YoY: +2.7% EPS YoY: +15.0% Move: +1.16%
Prestige Consumer
PBH
$66.11 1.16%
Exchange NYSE Sector Healthcare Industry Medical Distribution
Q3 2025
Published: Feb 6, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for PBH

Reported

Report Date

Feb 6, 2025

Quarter Q3 2025

Revenue

290.32M

YoY: +2.7%

EPS

1.22

YoY: +15.0%

Market Move

+1.16%

Previous quarter: Q2 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $290.32M up 2.7% year-over-year
  • EPS of $1.22 increased by 15% from previous year
  • Gross margin of 55.5%
  • Net income of 61.03M
  • ""We've reduced our variable term loan debt balance to zero and continued to opportunistically repurchase shares, while improving our leverage ratio to 2.5x."" - Ron Lombardi
PBH
Prestige Consumer Healthcare Inc

Executive Summary

In Q3 2025, Prestige Consumer Healthcare Inc reported robust performance, achieving record sales of $290.3 million, a 2.7% increase year-over-year despite industry challenges. The increase reflects the company’s effective capital allocation strategies and growth in its international markets, particularly the Hydralyte brand. EBITDA margins remained solid in the low 30s, with a notable 15% rise in earnings per share (EPS) to a record $1.22, bolstered by reduced interest expenses and disciplined share repurchases. The management's outlook remains positive, with expectations for a strong finish in Q4, anticipating revenues parallel to Q3, and addressing potential headwinds from global tariff implications.

Key Performance Indicators

Revenue
Increasing
290.32M
QoQ: 2.39% | YoY: 2.68%
Gross Profit
Increasing
161.05M
55.47% margin
QoQ: 2.33% | YoY: 1.97%
Operating Income
Increasing
91.96M
QoQ: 9.04% | YoY: 5.91%
Net Income
Increasing
61.03M
QoQ: 12.24% | YoY: 15.05%
EPS
Increasing
1.23
QoQ: 11.82% | YoY: 14.95%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 249.53 0.95 -6.6% View
Q4 2025 296.76 1.00 +7.1% View
Q3 2025 290.32 1.22 +2.7% View
Q2 2025 283.55 1.09 -1.0% View
Q1 2025 267.14 0.98 -4.4% View